The Shareholders Foundation announced that an investigation on behalf of investors of Advaxis, Inc. (NASDAQ:ADXS) shares was launched over potential securities laws violations by Advaxis, Inc. and certain of its directors and officers.
Investors who purchased shares of Advaxis, Inc. (NASDAQ:ADXS) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Advaxis, Inc. (NASDAQ:ADXS) concerning whether a series of statements by Advaxis, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Shares of Advaxis, Inc. (NASDAQ:ADXS) grew from under $3 per share in November 2014 to as high as $13.74 per share on January 20, 2015.
Then January 21, 2015 an article was published that alleged that Advaxis, Inc. misstated the tumor response data for its ADXS-HPV drug in a recent corporate presentation, overstating its effectiveness in shrinking tumors.
Shares of Advaxis, Inc. (NASDAQ:ADXS) declined from $13.74 per share on January 20, 2015 to as low as $6.80 per share on January 22, 2015.
On January 30, 2015, NASDAQ:ADXS shares closed at $9.85 per share.
Those who purchased shares of Advaxis, Inc. have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com